-1-:

David Croteau1, Tiffany Kim1, Vicky Chan1

  • 1Division of Pharmacovigilance I, Office of Surveillance and Epidemiology (DC, TK, VC, AB), Center for Drug Evaluation and Research, U.S. Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.

概括

长期使用基-1-酸盐受体 (S1PR) 调制剂 (≥18个月) 是逐渐多焦点白内障 (PML) 的重要危险因素. 这一发现导致了这些多发性硬化症治疗的更新处方信息.